Key takeaways
Rinvoq (upadacitinib) and Zeposia (ozanimod) are both medications used to treat ulcerative colitis (UC), but they belong to different drug classes. Rinvoq is a Janus kinase (JAK) inhibitor, while Zeposia is a sphingosine 1-phosphate (S1P) receptor modulator. Rinvoq is also used for a variety of other inflammatory conditions, such as rheumatoid arthritis and eczema, whereas Zeposia is additionally approved for relapsing forms of multiple sclerosis (MS). Rinvoq is available as an extended-release tablet and an oral solution, typically taken once daily, while Zeposia is taken as a capsule once daily, with a starter pack to gradually increase the dose. Common side effects of Rinvoq include infections and acne, while Zeposia may cause upper respiratory infections and changes in liver tests. Both medications can increase the risk of infections, but Zeposia also has specific warnings about changes in heart rate and blood pressure. Both medications require careful monitoring for side effects and interactions with other medications.
